Measles-Mumps-Rubella-Varicella Combination Vaccine (ProQuad(A (R))): A Guide to Its Use in Children in the EU

作者：Scott Lesley J^*

来源：Pediatric Drugs, 2015, 17(2): 167-174.

DOI：10.1007/s40272-015-0123-7

In the EU, the live attenuated, tetravalent measles-mumps-rubella-varicella vaccine ProQuad(A (R)) is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age using a two-dose schedule and may be used in infants from 9 months of age to conform with a national vaccination schedule, outbreak situations or travel to a region with a high prevalence of measles. Clinical data in young children indicates that vaccination with ProQuad(A (R)) is as immunogenic as the component vaccines, provides long-term protection against these potentially serious childhood infections and has an acceptable safety profile. Combining the viral strains of the measles-mumps-rubella vaccine M-M-RVAXPRO(A (R)) and the varicella vaccine Varivax(A (R)) in ProQuad(A (R)) reduces the complexity of vaccination schedules, thereby potentially improving vaccination coverage and the timeliness of vaccination.

• 出版日期2015-4